With headquarters in Basel, Switzerland, Novartis is recognised as being one of the strongest performing pharmaceutical companies in terms of sales, high revenue growth, acquisitions
May 1, 2007 (Press Release) --
With headquarters in Basel, Switzerland, Novartis is recognised as being one of the strongest performing pharmaceutical companies in terms of sales, high revenue growth, acquisitions, breadth of portfolio, product launches and pipeline developments. In 2006 - ten years after its inception - Novartis generated total net sales of $37bn worldwide.
Novartis Market Outlook 2012 Report, examines the Novartis group independently and critically, through comprehensive research and analysis. Importantly, Its discusses Novartis in the context of the wider pharmaceutical industry and market. This market-based research involved a detailed study of commercial documents, databases, company reports and relevant news. Importantly, Its applied techniques such as financial forecasting, SWOT analyses and qualitative projections. The result is a comprehensive market-based report with detailed analysis and informed opinion.
In particular, Novartis 2007-2012 concentrates on the following essential aspects of the company:
Detailed analysis of Novartis divisions and its products, including Sandoz
Sales forecasts for key products by therapeutic area
Discussions of issues affecting the relevant market segments, including competitor analysis
Sales forecasts for all the Novartis divisions and the overall group
Drivers and opportunities for Novartis
Restraints and threats facing the company
Discussions of company strategy in the context of the market
Pipeline developments and their implications for the future
Strategic alliances and licensing
International operations
Novartis appears to have a golden touch that even other leading global pharmaceutical companies envy. In 2005, Novartis generated the fourth-highest sales in the global pharmaceutical industry, coming behind Pfizer, GSK and Sanofi-Aventis respectively. With its above-average growth, visiongain predicts that Novartis will rise even higher in the ranks of pharmaceutical giants within the foreseeable future. In particular, there will be significant developments in R&D and international operations.
Unique benefits to you when you order this report
- Full searchable report when you buy the company or corporate editions
- Immediate access through our exclusive Reading Room
- You can access your report whichever country you are in without using harddrive space
- Primary research throughout. You will not find this information anywhere else
- Report stored in your reading room for ever
- Copies can be printed off for offline reading
- Packed with charts, analysis, figures, graphs and tables
For more information, Please visit : http://www.bharatbook.com/detail.asp?id=42582
or email us at : info@bharatbook.com
You can also call us at +91-(022)-2757 8668 or +91-(022)-2757 9131
Novartis Market Outlook 2012 Report, examines the Novartis group independently and critically, through comprehensive research and analysis. Importantly, Its discusses Novartis in the context of the wider pharmaceutical industry and market. This market-based research involved a detailed study of commercial documents, databases, company reports and relevant news. Importantly, Its applied techniques such as financial forecasting, SWOT analyses and qualitative projections. The result is a comprehensive market-based report with detailed analysis and informed opinion.
In particular, Novartis 2007-2012 concentrates on the following essential aspects of the company:
Detailed analysis of Novartis divisions and its products, including Sandoz
Sales forecasts for key products by therapeutic area
Discussions of issues affecting the relevant market segments, including competitor analysis
Sales forecasts for all the Novartis divisions and the overall group
Drivers and opportunities for Novartis
Restraints and threats facing the company
Discussions of company strategy in the context of the market
Pipeline developments and their implications for the future
Strategic alliances and licensing
International operations
Novartis appears to have a golden touch that even other leading global pharmaceutical companies envy. In 2005, Novartis generated the fourth-highest sales in the global pharmaceutical industry, coming behind Pfizer, GSK and Sanofi-Aventis respectively. With its above-average growth, visiongain predicts that Novartis will rise even higher in the ranks of pharmaceutical giants within the foreseeable future. In particular, there will be significant developments in R&D and international operations.
Unique benefits to you when you order this report
- Full searchable report when you buy the company or corporate editions
- Immediate access through our exclusive Reading Room
- You can access your report whichever country you are in without using harddrive space
- Primary research throughout. You will not find this information anywhere else
- Report stored in your reading room for ever
- Copies can be printed off for offline reading
- Packed with charts, analysis, figures, graphs and tables
For more information, Please visit : http://www.bharatbook.com/detail.asp?id=42582
or email us at : info@bharatbook.com
You can also call us at +91-(022)-2757 8668 or +91-(022)-2757 9131
Email
Print
SPAM
